Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaeal1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 29	JUN 25	CA/CAplus and USPAT databases updated with IPC

<12/04/2007> Erich Leese

```
                  reclassification data
 NEWS 30  JUN 30  AEROSPACE enhanced with more than 1 million U.S.
                  patent records
 NEWS 31  JUN 30  EMBASE, EMBAL, and LEMBASE updated with additional
                  options to display authors and affiliated
                  organizations
 NEWS 32  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 33  JUN 30  STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:39:05 ON 30 JUN 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:39:14 ON 30 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 JUN 2008  HIGHEST RN 1031692-95-1
DICTIONARY FILE UPDATES:  29 JUN 2008  HIGHEST RN 1031692-95-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:
```

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10567310species.str





chain nodes :
14 15 16 17 19 20 21 22 24 25 26 27 28 29 30 31 35 36 37 38 39
40
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-36 2-20 3-38 4-37 5-8 6-35 7-24 7-25 9-30 9-31 10-28 10-29 11-14
12-26 12-27 14-15 15-16 15-19 16-17 17-39 20-21 20-22 39-40
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-36 3-38 4-37 5-8 6-35 7-8 7-12 7-24 7-25 8-9 9-10 9-30 9-31 10-11
10-28 10-29 11-12 11-14 12-26 12-27 14-15 15-16 15-19 16-17 17-39 20-21
20-22 39-40
exact bonds :
2-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 :

G1:Cb,Ak

G2:H,O

G3:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

L1 STRUCTURE UPLOADED

=> s l1 full
FULL SEARCH INITIATED 17:39:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 150564 TO ITERATE

100.0% PROCESSED 150564 ITERATIONS 14 ANSWERS
SEARCH TIME: 00.00.03

L2 14 SEA SSS FUL L1

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Ak

G2 H,O

G3 C,H

Structure attributes must be viewed using STN Express query preparation.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	178.57

FILE 'CAPLUS' ENTERED AT 17:40:00 ON 30 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Jun 2008 VOL 149 ISS 1
FILE LAST UPDATED: 29 Jun 2008 (20080629/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2 full
L3 3 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:90959 CAPLUS
DOCUMENT NUMBER: 148:193100
TITLE: Photolatent bases for polyurethane adhesives
INVENTOR(S): Studer, Katja; Jung, Tunja; Dietliker, Kurt
PATENT ASSIGNEE(S): CIBA Specialty Chemicals Holding Inc., Switz.
SOURCE: PCT Int. Appl., 23pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008009575	A2	20080124	WO 2007-EP56917	20070709
WO 2008009575	A3	20080327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2006-117329 A 20060717

AB A method of bonding a first substrate to a second substrate, comprises the steps of (a) applying an UV-curable adhesive resin composition comprising a photolatent base to at least one transparent surface of at least one of said first and second substrates, (b) bringing said first and second substrates together with said adhesive composition there between, (c) exposing said adhesive composition to actinic radiation to effect curing.

IT 1003309-81-6
RL: CAT (Catalyst use); USES (Uses)
(photolatent base; photolatent bases for adhesives)

RN 1003309-81-6 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[4-[2-(dimethylamino)-1-oxo-2-(phenylmethyl)butyl]phenyl]-, 1,1'-[oxybis(2,1-ethanediyloxy-2,1-ethanediyl)] ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:456844 CAPLUS
DOCUMENT NUMBER: 144:469729
TITLE: Piperazino based multi-functional photoinitiators, preparation and uses
INVENTOR(S): Herlihy, Shaun Lawrence; Rowatt, Brian; Davidson, Robert Stephen
PATENT ASSIGNEE(S): Sun Chemical Limited, UK
SOURCE: Brit. UK Pat. Appl., 27 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2420117	A	20060517	GB 2004-24831	20041110
AU 2005326556	A1	20060810	AU 2005-326556	20051109
CA 2587383	A1	20060810	CA 2005-2587383	20051109
WO 2006082477	A1	20060810	WO 2005-IB4157	20051109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1812414	A1	20070801	EP 2005-856268	20051109
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008519760	T	20080612	JP 2007-539660	20051109
CN 101133041	A	20080227	CN 2005-80038507	20070510
IN 2007DN04356	A	20070824	IN 2007-DN4356	20070607
KR 2007092228	A	20070912	KR 2007-712941	20070608
US 20080045620	A1	20080221	US 2007-718952	20070927

PRIORITY APPLN. INFO.: GB 2004-24831 A 20041110
WO 2005-IB4157 W 20051109

OTHER SOURCE(S): MARPAT 144:469729
GI



I

AB An aminoacetophenone-substituted piperazine compound is of formula I, wherein the substituents R1 are individually selected from C1-C10 alkyl groups and optionally substituted benzyl groups; the substituents R2 are individually selected from alkyl groups or, together with the nitrogen atom to which they are attached, represent a nitrogen-containing heterocyclic group; Z is selected from C6-C10 arylene groups and groups of formula --(CHR3)n--, where R3 is a hydrogen atom, a hydroxy group or a C1-C4 alkyl group, and n is a number from 0 to 6; Y is selected from carbonyl groups and the -CH2- group; Q is selected from the residues of mono- or polyhydroxy compds. having from 1 to 6 hydroxy groups; and x is a number from 1 to 6; and esters thereof. Preferred possibilities for Q include residues of ethylene glycol, propylene glycol, butylene glycol, glycerol, 2,2-propanediol, polyethylene glycol, polypropylene glycol, trimethylolpropane, di-trimethylolpropane, pentaerythritol and di-pentaerythritol. These compds. may be useful as multi-functional photoinitiators for use in coating compns. to be cured by radiant energy.

IT 886463-10-1P 886463-11-2P 886463-12-3P
886463-13-4P 886463-14-5P 886463-15-6P
RL: CAT (Catalyst use); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(piperazino based multi-functional photoinitiators, preparation and uses)

RN 886463-10-1 CAPLUS

CN Poly(oxy-1,2-ethanediyl), α-[3-[4-[4-[2-(dimethylamino)-2-(phenylmethyl)-1-oxobutyl]phenyl]-1-piperazinyl]-1-oxopropyl]-ω-[3-[4-[4-[2-(dimethylamino)-2-(phenylmethyl)-1-oxobutyl]phenyl]-1-piperazinyl]-1-oxopropoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 886463-11-2 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[4-[2-(dimethylamino)-1-oxo-2-(phenylmethyl)butyl]phenyl]-, 2,2-bis[[3-[4-[4-[2-(dimethylamino)-1-oxo-2-(phenylmethyl)butyl]phenyl]-1-piperazinyl]-1-oxopropoxy]methyl]butyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 886463-12-3 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[4-[2-(dimethylamino)-1-oxo-2-(phenylmethyl)butyl]phenyl]-, 2,2-bis[[3-[4-[4-[2-(dimethylamino)-1-oxo-2-

(phenylmethyl)butyl]phenyl]-1-piperazinyl]-1-oxopropoxy]methyl]-1,3-propanediyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 2-B



PAGE 3-A



RN 886463-13-4 CAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[3-[4-[4-[2-methyl-2-(4-morpholinyl)-1-oxopropyl]phenyl]-1-piperazinyl]-1-oxopropyl]-ω-[3-[4-[4-[2-methyl-2-(4-morpholinyl)-1-oxopropyl]phenyl]-1-piperazinyl]-1-oxopropoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 886463-14-5 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[4-[2-methyl-2-(4-morpholinyl)-1-oxopropyl]phenyl]-, 2,2-bis[[3-[4-[4-[2-methyl-2-(4-morpholinyl)-1-oxopropyl]phenyl]-1-piperazinyl]-1-oxopropoxy]methyl]butyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 886463-15-6 CAPLUS
CN 1-Piperazinepropanoic acid, 4-[4-[2-methyl-2-(4-morpholinyl)-1-oxopropyl]phenyl]-, 2,2-bis[[3-[4-[4-[2-methyl-2-(4-morpholinyl)-1-oxopropyl]phenyl]-1-piperazinyl]-1-oxopropoxy]methyl]-1,3-propanediyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 2-B



PAGE 3-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:8311 CAPLUS
DOCUMENT NUMBER: 142:116228
TITLE: Piperazine-based radiation curing sensitizers
INVENTOR(S): Davidson, Robert Stephen; Herlihy, Shaun Lawrence; Rowatt, Brian
PATENT ASSIGNEE(S): Sun Chemical Limited, UK
SOURCE: Brit. UK Pat. Appl., 28 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2403478	A	20050105	GB 2003-15774	20030704
WO 2005007637	A1	20050127	WO 2004-US21370	20040702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1660470	A1	20060531	EP 2004-777489	20040702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1845912	A	20061011	CN 2004-80025346	20040702
US 20070066700	A1	20070322	US 2006-567310	20061129
PRIORITY APPLN. INFO.:			GB 2003-15774 A	20030704
			WO 2004-US21370 W	20040702

OTHER SOURCE(S): MARPAT 142:116228
GI



I

AB A piperazine-based compound of formula I and esters thereof are useful as sensitizers for use in radiation-curable compns., wherein: R1 represents a Me group, an Et group, a C5 or C6 cycloalkyl group or a C6 - C10 aryl group, said aryl group being unsubstituted or being substituted by at least one C1 - C4 alkyl or alkoxy group; Z represents a C6 - C10 arylene group or a group of formula --(CHR4)n--, where R4 represents a hydrogen atom, a hydroxy group or a C1 - C4 alkyl group, and n is a number from 0 to 6; Y represents a carbonyl group or a --CH2-- group, provided that R4 represents a hydroxy group when Y represents a --CH2-- group; Q represents a residue of a mono- or poly-hydroxy compound having from 1 to 6 hydroxy

groups; and x is a number from 1 to 6.

IT 819866-14-3P 819866-15-4P 819866-17-6P
819866-18-7P 819866-20-1P 820232-39-1P
820232-41-5P
RL: PRP (Properties); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(piperazine-based radiation curing sensitizers)

RN 819866-14-3 CAPLUS

CN Poly(oxy-1,2-ethanediyl), α-hydro-ω-[3-[4-(4-acetylphenyl)-1-piperazinyl]-1-oxopropoxy]-, ether with 2-ethyl-2-(hydroxymethyl)-1,3-propanediol (3:1) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 819866-15-4 CAPLUS

CN Poly(oxy-1,2-ethanediyl), α-hydro-ω-[3-[4-(4-acetylphenyl)-1-piperazinyl]-1-oxopropoxy]-, ether with 2,2-bis(hydroxymethyl)-1,3-propanediol (4:1) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 819866-17-6 CAPLUS
CN Poly(oxy-1,4-butanediyl), α-[[4-(4-acetylphenyl)-1-piperazinyl]acetyl]-ω-[[[4-(4-acetylphenyl)-1-piperazinyl]acetyl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 819866-18-7 CAPLUS
CN Poly(oxy-1,4-butanediyl), α-[2-[4-(4-acetylphenyl)-1-piperazinyl]-1-oxopropyl]-ω-[2-[4-(4-acetylphenyl)-1-piperazinyl]-1-oxopropoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 819866-20-1 CAPLUS
CN Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, ether with 2,2-bis(hydroxymethyl)-1,3-propanediol (4:1), bis[4-(4-acetylphenyl)-1-piperazinepropanoate] di-2-propenoate (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 820232-39-1 CAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α,α'-(2,2-dimethyl-1,3-propanediyl)bis[ω-[3-[4-(4-acetylphenyl)-1-piperazinyl]-1-oxopropoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 820232-41-5 CAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α,α',α''-1,2,3-propanetriyltris[ω-[3-[4-(4-acetylphenyl)-1-piperazinyl]-1-oxopropoxy]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      22.11     200.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.40      -2.40

FILE 'REGISTRY' ENTERED AT 17:47:00 ON 30 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 JUN 2008  HIGHEST RN 1031692-95-1
DICTIONARY FILE UPDATES:  29 JUN 2008  HIGHEST RN 1031692-95-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10567310election.str
```





chain nodes :
14 15 16 17 19 20 21 22 25 26 27 28 29 30 31 32
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
5-8 7-25 7-26 9-31 9-32 10-29 10-30 11-14 12-27 12-28 14-15 15-16 15-19
16-17 20-21 20-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
5-8 7-8 7-12 7-25 7-26 8-9 9-10 9-31 9-32 10-11 10-29 10-30 11-12
11-14 12-27 12-28 14-15 15-16 15-19 16-17 20-21 20-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 :

G1:Cb,Ak

G2:H,O

G3:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS

L4 STRUCTURE UPLOADED

=> s l4 full
FULL SEARCH INITIATED 17:47:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 713335 TO ITERATE

100.0% PROCESSED 713335 ITERATIONS 117 ANSWERS
SEARCH TIME: 00.00.06

L5 117 SEA SSS FUL L4

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	379.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.40

FILE 'CAPLUS' ENTERED AT 17:47:32 ON 30 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Jun 2008 VOL 149 ISS 1
FILE LAST UPDATED: 29 Jun 2008 (20080629/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l5 full
L6   7 L5

=> d ibib abs hitstr tot

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1257556 CAPLUS
DOCUMENT NUMBER: 147:180509
TITLE: Estimation of phospholipophilicity of 1-[3-(arylpiperazin-1-yl)-propyl]-pyrrolidin-2-one derivatives on immobilized artificial membrane stationary phase and its correlation with biological data
AUTHOR(S): Kulig, Katarzyna; Malawska, Barbara
CORPORATE SOURCE: Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Medical College Jagiellonian University, Krakow, 30-688, Pol.
SOURCE: Biomedical Chromatography (2006), 20(11), 1129-1135
CODEN: BICHE2; ISSN: 0269-3879
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A mol. library containing 42 1-[3-(arylpiperazin-1-yl)-propyl]-pyrrolidin-2-one derivs. has been designed and synthesized. The phospholipophilicity of the obtained compds. has been determined using immobilized artificial membrane high-performance liquid chromatog. (IAM-HPLC). The performed anal. allowed the calcn. of log kwe values for each of the tested compds. Exptl. phospholipophilicity data (log kwe) has been compared with the affinity of the tested compds. to α2-adrenoceptors. Performed quant. structure-activity relationship studies indicated that, for the tested compds., there are dependences between affinity for α2-adrenoceptors and their log kwe values. The obtained results confirmed that the applied chromatog. IAM-HPLC method could be useful in fast characterization of the phospholipophilicity of structurally closely related compds. as well as for larger series of compds., such as drug candidates. It could also be used as a tool for further research into this group of compds.
IT 944402-80-6
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phospholipophilicity of 1-[3-(arylpiperazin-1-yl)-propyl]-pyrrolidin-2-one derivs. dependence on affinity for α2-adrenoceptors for drug discovery)
RN 944402-80-6 CAPLUS
CN 2-Pyrrolidinone, 1-[3-[4-(2-acetylphenyl)-1-piperazinyl]-2-methoxypropyl]- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1330455 CAPLUS
DOCUMENT NUMBER: 144:51611
TITLE: Preparation of disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
INVENTOR(S): Sonesson, Clas; Swanson, Lars; Waters, Nicholas
PATENT ASSIGNEE(S): A. Carlsson Research AB, Swed.
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005121087	A1	20051222	WO 2005-EP6147	20050608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005251906	A1	20051222	AU 2005-251906	20050608
AU 2005251909	A1	20051222	AU 2005-251909	20050608
CA 2569840	A1	20051222	CA 2005-2569840	20050608
CA 2569843	A1	20051222	CA 2005-2569843	20050608
WO 2005121088	A1	20051222	WO 2005-EP6154	20050608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1768958	A1	20070404	EP 2005-746589	20050608
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP 1773772	A1	20070418	EP 2005-760618	20050608
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1997630	A	20070711	CN 2005-80023206	20050608
CN 1997631	A	20070711	CN 2005-80023251	20050608
BR 2005011907	A	20080115	BR 2005-11907	20050608
JP 2008501747	T	20080124	JP 2007-526287	20050608

JP 2008501749	T	20080124	JP 2007-526289		20050608
MX 2006PA13944	A	20071008	MX 2006-PA13944		20061130
MX 2006PA13941	A	20071210	MX 2006-PA13941		20061130
US 20070179185	A1	20070802	US 2006-567925		20061207
US 20070149542	A1	20070628	US 2006-608313		20061208
IN 2007DN00067	A	20070803	IN 2007-DN67		20070102
NO 2007000124	A	20070308	NO 2007-124		20070108
KR 2007050425	A	20070515	KR 2007-700513		20070108
PRIORITY APPLN. INFO.:			SE 2004-1464	A	20040608
			US 2004-577953P	P	20040608
			SE 2004-3142	A	20041220
			US 2004-637530P	P	20041220
			WO 2005-EP6147	W	20050608
			WO 2005-EP6154	W	20050608

OTHER SOURCE(S): CASREACT 144:51611; MARPAT 144:51611

GI



I

AB Title compds. I [X = N, CH; R1 = OSO2CF3, OSO2CH3, NHSO2CH3, etc.; R2 = CN, CF3, OH, NH2, etc.; R3 = alkyl, allyl, CH2CH2OCH3, etc.] are prepared For instance, 4-[2-fluoro-3-(methylsulfonyl)phenyl]-1-propylpiperidine (II) is prepared in 5 steps from 4-[2-fluoro-3-(methylthio)phenyl]-1,2,3,6-tetrahydropyridine and 1-iodopropane. II had ED50 = 28 μmol/kg on increase of DOPAC (3,4-dihydroxyphenylacetic acid) in the rat striatum. I have therapeutic effects against disorders in the central nervous system.

IT 871355-49-6P, 1-[3-[4-(2-Methoxyethyl)piperazin-1-yl]-2-methylphenyl]ethanone 871355-53-2P, 1-[2-Fluoro-3-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]ethanone 871355-57-6P, 2-Acetyl-6-[4-(2-methoxyethyl)piperazin-1-yl]benzonitrile 871355-61-2P, 1-[2-Chloro-3-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]ethanone 871357-07-2P, 2,2,2-Trifluoro-1-[3-[4-(2-methoxyethyl)piperazin-1-yl]-2-methylphenyl]ethanone 871357-11-8P , 2,2,2-Trifluoro-1-[2-fluoro-3-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]ethanone 871357-15-2P, 2-[4-(2-Methoxyethyl)piperazin-1-yl]-6-(trifluoroacetyl)benzonitrile 871357-20-9P, 1-[2-Chloro-3-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-2,2,2-trifluoroethanone
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission)

RN 871355-49-6 CAPLUS

CN Ethanone, 1-[3-[4-(2-methoxyethyl)-1-piperazinyl]-2-methylphenyl]- (CA INDEX NAME)



RN 871355-53-2 CAPLUS
CN Ethanone, 1-[2-fluoro-3-[4-(2-methoxyethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 871355-57-6 CAPLUS
CN Benzonitrile, 2-acetyl-6-[4-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 871355-61-2 CAPLUS
CN Ethanone, 1-[2-chloro-3-[4-(2-methoxyethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 871357-07-2 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-[3-[4-(2-methoxyethyl)-1-piperazinyl]-2-methylphenyl]- (CA INDEX NAME)



RN 871357-11-8 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-[2-fluoro-3-[4-(2-methoxyethyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 871357-15-2 CAPLUS
CN Benzonitrile, 2-[4-(2-methoxyethyl)-1-piperazinyl]-6-(2,2,2-trifluoroacetyl)- (CA INDEX NAME)



RN 871357-20-9 CAPLUS
CN Ethanone, 1-[2-chloro-3-[4-(2-methoxyethyl)-1-piperazinyl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1078248 CAPLUS
DOCUMENT NUMBER: 143:360127
TITLE: Preparation of diagnostic and therapeutic alkyl piperidine/piperazine compounds for neuron imaging and treating neurodegenerative disease
INVENTOR(S): Elmaleh, David R.; Songwoon, Choi; Fishman, Alan J.
PATENT ASSIGNEE(S): The General Hospital Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050222166	A1	20051006	US 2004-814118	20040331
US 7381822	B2	20080603		
PRIORITY APPLN. INFO.:			US 2004-814118	20040331

OTHER SOURCE(S): CASREACT 143:360127; MARPAT 143:360127
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Piperidine or piperazine compds. useful for treating neurodegenerative diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided. The compds. are characterized by the formulas I-V : m = 1-6; X, Y, Z1, Z2, and Z3 = H, halo, haloalkyl, alkyl, aryl, (C1-C6) alkoxy, N-alkyl,(C2-C6) acyloxy, N-alkylene, -SH, -SR, wherein R is from the same group as R1 and R2, NH2, NO, CN, OH, COOR6, C(O)NR5R4, NR3R2, or S(O)kR1 wherein k = 1 or 2 and R1 to R6 = H or (C1-C6)alkyl; R1 and R2 = H, (C1-C6) alkyl, hydroxyalkyl or mercaptoalkyl, -COOR1, CN, (C1-C6)alkenyl, (C2-C6)alkynyl, or (un)substituted 1,2,4-oxadiazol-5-yl; R7= H, O or Ph; R8 = H, Ph, halophenyl, nitrophenyl, pyridyl, piperonyl or sulfoxonitrophenyl; W = O or S; T = NH2 or C1-C6 aminoalkyl; A = N or C; T= C1-C6 alkyl or sulfonyl; Q=NH2 or C1-C6 amino alkyl.

IT 728946-06-3P, 1-[4-[4-[4-[Bis(4-fluorophenyl)methoxy]butyl]piperazin-1-yl]phenyl]ethanone oxalate
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of diagnostic and therapeutic alkyl piperidine/piperazine compds. for neuron imaging and treating neurodegenerative disease)

RN 728946-06-3 CAPLUS
CN Ethanone, 1-[4-[4-[4-[bis(4-fluorophenyl)methoxy]butyl]-1-piperazinyl]phenyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 728946-05-2
CMF C29 H32 F2 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:8311 CAPLUS
DOCUMENT NUMBER: 142:116228
TITLE: Piperazine-based radiation curing sensitizers
INVENTOR(S): Davidson, Robert Stephen; Herlihy, Shaun Lawrence; Rowatt, Brian
PATENT ASSIGNEE(S): Sun Chemical Limited, UK
SOURCE: Brit. UK Pat. Appl., 28 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2403478	A	20050105	GB 2003-15774	20030704
WO 2005007637	A1	20050127	WO 2004-US21370	20040702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1660470	A1	20060531	EP 2004-777489	20040702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1845912	A	20061011	CN 2004-80025346	20040702
US 20070066700	A1	20070322	US 2006-567310	20061129
PRIORITY APPLN. INFO.:			GB 2003-15774 A	20030704
			WO 2004-US21370 W	20040702

OTHER SOURCE(S): MARPAT 142:116228
GI



AB A piperazine-based compound of formula I and esters thereof are useful as sensitizers for use in radiation-curable compns., wherein: R1 represents a Me group, an Et group, a C5 or C6 cycloalkyl group or a C6 - C10 aryl group, said aryl group being unsubstituted or being substituted by at least one C1 - C4 alkyl or alkoxy group; Z represents a C6 - C10 arylene group or a group of formula --(CHR4)n--, where R4 represents a hydrogen atom, a hydroxy group or a C1 - C4 alkyl group, and n is a number from 0 to 6; Y represents a carbonyl group or a --CH2-- group, provided that R4 represents a hydroxy group when Y represents a --CH2-- group; Q represents a residue of a mono- or poly-hydroxy compound having from 1 to 6 hydroxy

groups; and x is a number from 1 to 6.

IT 819866-13-2P
RL: PRP (Properties); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(piperazine-based radiation curing sensitizers)

RN 819866-13-2 CAPLUS

CN Ethanone, 1-[4-[4-[3-[2,2-bis[[3-[4-(4-acetylphenyl)-1-piperazinyl]-2-hydroxypropoxy]methyl]butoxy]-2-hydroxypropyl]-1-piperazinyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:606436 CAPLUS
DOCUMENT NUMBER: 141:157135
TITLE: Preparation of piperidine and piperazine derivatives with dopaminergic neurotransmitter system activity for diagnostic and therapeutic uses
INVENTOR(S): Elmaleh, David R.; Choi, Sangwoon; Fishman, Alan J.
PATENT ASSIGNEE(S): The General Hospital Corporation, USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063150	A2	20040729	WO 2003-US41731	20031231
WO 2004063150	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300147	A1	20040810	AU 2003-300147	20031231
PRIORITY APPLN. INFO.:			US 2003-437885P P	20030106
			WO 2003-US41731 W	20031231

OTHER SOURCE(S): MARPAT 141:157135
GI



I

AB Piperazine derivs., such as I [R7 = H, Ph, :O; R8 = H, Ph, COMe, COPh, halophenyl, nitrophenyl, nitrophenylsulfonyl, piperonyl], were prepared for use in treating neurodegenerative diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons. Thus, piperazine derivative II (R7 = R8 = H) was prepared via an amination reaction with 30% yield of (F-4-C6H4)2CHO(CH2)4Cl and piperazine using K2CO3 in DMF. The prepared piperazines were assayed. for binding affinities at the

DA, 5-HT and NE transporters labeled with [125I]RTI-55.

IT 728946-05-2P 728946-06-3P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine and piperazine derivs. with dopaminergic neurotransmitter system activity for diagnostic and therapeutic uses)

RN 728946-05-2 CAPLUS
CN Ethanone, 1-[4-[4-[4-[bis(4-fluorophenyl)methoxy]butyl]-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 728946-06-3 CAPLUS
CN Ethanone, 1-[4-[4-[4-[bis(4-fluorophenyl)methoxy]butyl]-1-piperazinyl]phenyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 728946-05-2
CMF C29 H32 F2 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:832759 CAPLUS
DOCUMENT NUMBER: 137:353062
TITLE: Preparation of 2-iminopyrrolidine derivatives as thrombin receptor antagonists
INVENTOR(S): Suzuki, Shuichi; Kotake, Makoto; Miyamoto, Mitsuaki; Kawahara, Tetsuya; Kajiwara, Akiharu; Hishinuma, Ieharu; Okano, Kazuo; Miyazawa, Syuhei; Clark, Richard; Ozaki, Fumihiro; Sato, Nobuaki; Shinoda, Masanobu; Kamada, Atsushi; Tsukada, Itaru; Matsuura, Fumiyoshi; Naoe, Yoshimitsu; Terauchi, Taro; Oohashi, Yoshiaki; Ito, Osamu; Tanaka, Hiroshi; Musya, Takashi; Kogushi, Motoji; Kawada, Tsutomu; Matsuoka, Toshiyuki; Kobayashi, Hiroko; Chiba, Kenichi; Kimura, Akifumi; Ono, Naoto
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 948 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085855	A1	20021031	WO 2002-JP3961	20020419
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446924	A1	20021031	CA 2002-2446924	20020419
AU 2002255269	A1	20021105	AU 2002-255269	20020419
AU 2002255269	B2	20070315		
EP 1391451	A1	20040225	EP 2002-724628	20020419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008985	A	20040309	BR 2002-8985	20020419
CN 1503784	A	20040609	CN 2002-808565	20020419
HU 2004000467	A2	20050228	HU 2004-467	20020419
EP 1614680	A2	20060111	EP 2005-22069	20020419
EP 1614680	A3	20060201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
CN 1733725	A	20060215	CN 2005-10080404	20020419
RU 2270192	C2	20060220	RU 2003-133664	20020419
CN 1754880	A	20060405	CN 2005-10080403	20020419
JP 3795458	B2	20060712	JP 2002-583382	20020419
NZ 528820	A	20070126	NZ 2002-528820	20020419
NO 2003004632	A	20031219	NO 2003-4632	20031016
MX 2003PA09497	A	20040524	MX 2003-PA9497	20031016
ZA 2003008064	A	20050207	ZA 2003-8064	20031016
KR 749794	B1	20070817	KR 2003-713674	20031018

IN 2003DN01719	A	20051014	IN 2003-DN1719		20031020
US 20050004204	A1	20050106	US 2004-475188		20040609
US 7244730	B2	20070717			
AU 2005202135	A1	20050609	AU 2005-202135		20050517
AU 2005202135	B2	20071115			
KR 749795	B1	20070817	KR 2005-709505		20050526
US 20050245592	A1	20051103	US 2005-158941		20050622
JP 2006206595	A	20060810	JP 2006-41270		20060217
JP 2006225393	A	20060831	JP 2006-41255		20060217
PRIORITY APPLN. INFO.:			JP 2001-121829	A	20010419
			JP 2001-269422	A	20010905
			AU 2002-255269	A3	20020419
			CN 2002-808565	A3	20020419
			EP 2002-724628	A3	20020419
			JP 2002-583382	A3	20020419
			WO 2002-JP3961	W	20020419
			KR 2003-713674	A3	20031018
			US 2004-475188	A1	20040609

OTHER SOURCE(S): MARPAT 137:353062

GI



I



II

AB 2-Iminopyrrolidine derivs. including 2,3-dihydro-1H-isoindole and 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine represented by the general formula (I) or salts thereof [wherein B = (un)substituted aromatic hydrocarbon or aromatic heterocyclic ring optionally containing 1 or 2 N atom(s); R101, R102, R103 = H, cyano, halo, each (un)substituted C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, acyl, CO2H, CONH2, C1-6 alkoxycarbonyl, C1-6 alkylaminocarbonyl, HO, C1-6 alkoxy, C3-8 cycloalkyloxy, NH2, C1-6 alkylamino, C3-8 cycloalkylamino, acylamino, ureido, sulfonylamino, sulfonyl, SO2NH2, or C3-8 cycloalkyl, etc.; Y1 = a single bond, (CH2)m, each (un)substituted CH, CH2, NH, CONH, or SO2NH, CH2CO, SO, SO2, CO (wherein m = an integer of 1-3); Y2 = a single bond, O, N, (CH2)m, each (un)substituted CH, CH2, or

C(:NOH), CO, SO, SO2; Ar = H, (un)substituted Ph] are prepared These compds. are thrombin receptor antagonists, in particular thrombin PAR1 receptor antagonists and are useful as blood platelet aggregation inhibitors and proliferation inhibitors of smooth muscle cell, endothelial cell, fibroblast, kidney cell, osteosarcoma cell, muscle cell, cancer cell, and/or glial cell and for the treatment and/or prevention of thrombosis, vascular restenosis, deep vein thrombosis, lung embolism, cerebral infarction, heart disease, disseminated intravascular coagulation syndrome, hypertension, inflammation, rheumatism, asthma, glomerulonephritis, osteoporosis, nerve disease, and/or malignant tumor. Thus, [6-[(1-imino-1,3-dihydroisoindol-2-yl)acetyl]-2,3-dihydrobenz[1,4]oxazin-4-yl]acetonitrile derivative (II) in vitro showed IC50 of 0.017 μM for inhibiting the binding of [3H]Ala-(4-fluoro)Phe-Arg-(cyclohexyl)Ala-homoArg-Tyr-NH2 to thrombin receptor of human blood platelet, that of 0.29 μM for inhibiting the human blood platelet aggregation induced by thrombin, and that of 0.0061 μM for inhibiting the proliferation of rat smooth cell.

IT 474544-64-4P 474623-38-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydroisoindole and dihydro-5H-pyrrolo[3,4-b]pyridine derivs. as thrombin receptor antagonists and remedies and/or preventives for diseases)

RN 474544-64-4 CAPLUS
CN 1H-Isoindole-5-carboxamide, 2-[2-[3-(1,1-dimethylethyl)-4-methoxy-5-[4-(2-methoxyacetyl)-1-piperazinyl]phenyl]-2-oxoethyl]-6-ethoxy-2,3-dihydro-3-imino-N-methyl-, hydrobromide (1:1) (CA INDEX NAME)



RN 474623-38-6 CAPLUS
CN Ethanone, 2-(5,6-diethoxy-7-fluoro-1,3-dihydro-1-imino-2H-isoindol-2-yl)-1-[3-(1,1-dimethylethyl)-4-methoxy-5-[4-(2-methoxyacetyl)-1-piperazinyl]phenyl]-, hydrobromide (1:1) (CA INDEX NAME)



IT 474554-77-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydroisoindole and dihydro-5H-pyrrolo[3,4-b]pyridine derivs. as thrombin receptor antagonists and remedies and/or preventives for diseases)
RN 474554-77-3 CAPLUS
CN Piperazine, 1-[5-(bromoacetyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl]-4-(ethoxyacetyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 100 THERE ARE 100 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:246566 CAPLUS
DOCUMENT NUMBER: 134:280864
TITLE: Preparation of 6-azauracil derivatives as thyroid receptor ligands
INVENTOR(S): Dow, Robert Lee; Chiang, Yuan-Ching Phoebe; Estep, Kimberly Gail
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 153 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1088819	A2	20010404	EP 2000-308112	20000918
EP 1088819	A3	20010411		
EP 1088819	B1	20050615		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 297905	T	20050715	AT 2000-308112	20000918
PT 1088819	T	20050930	PT 2000-308112	20000918
ES 2240017	T3	20051016	ES 2000-308112	20000918
JP 2001114768	A	20010424	JP 2000-282882	20000919
JP 3763565	B2	20060405		
US 6787652	B1	20040907	US 2000-671668	20000927
CA 2321380	A1	20010330	CA 2000-2321380	20000928
CA 2321380	C	20060530		
BR 2000004539	A	20010417	BR 2000-4539	20000929
MX 2000PA09641	A	20020201	MX 2000-PA9641	20001002
US 20040157844	A1	20040812	US 2004-763451	20040123
US 6930107	B2	20050816		

PRIORITY APPLN. INFO.: US 1999-156842P P 19990930
US 2000-671668 A1 20000927
OTHER SOURCE(S): MARPAT 134:280864
GI



I

AB Title compds. [I; W = O, S, SO, SO2, NR30, CO, CH:CH, CH2, CHF, CF2, CH(OH); R1, R2 = H, halo, alkyl, cyano, OR12, CF3; R3 = H, halo, cyano, NO2, (substituted) alkyl, etc.; R4 = CR14R15R16, CONR19R20, aryl, heteroaryl, etc.; R3R4 = (CH2)b, Q(CH2)c, etc.; b = 3-7; c = 2-6; R5 =

OR23; R4R5 = CR31:CR32NH, CR31:CR32S, etc.; R7 = H, alkyl, haloalkyl, (CH2)nCO2R9; n = 0-3; R8 = H, alkyl, CO2R9, CONR10R11; R9 = (substituted) alkyl, alkenyl, dialkenyl, cycloalkyl, aryl, heterocyclyl; R10, R11 = H, (substituted) alkyl, cycloalkyl, alkenyl, heterocyclyl; R10R11 = heterocyclyl; R12 = H, (substituted) alkyl; R14 = H, alkyl, OR34; R15 = H, alkyl; R14R15 = O; R16 = H, (substituted) alkyl, alkylcycloalkyl, alkylaryl, alkylheterocyclyl; R19, R20 = H, (substituted) alkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, etc.; R23 = H, (substituted) alkyl, COR24; R24 = H, (substituted) alkyl, alkenyl, cycloalkyl, aryl, heteroaryl; R30 = H, (substituted) alkyl, alkenyl, cycloalkyl, COR31, etc.; R31 = H, (substituted) alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, etc.; R32 = H, (substituted) alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl; R34 = (substituted) aryl, heterocyclyl, alkyl, alkenyl, cycloalkyl], were prepared for treatment of obesity, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmia, glaucoma and heart failure (no data). Thus, [[[4-(3-bromo-4-methoxyphenoxy)-3,5-dimethylphenyl]hydrazono]cyanoacetyl]carbamic acid Et ester (preparation given) was heated with KOAc in HOAc at 120° for 5 h to give 2-[4-(3-bromo-4-methoxyphenoxy)-3,5-dimethylphenyl]-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile.

IT 332933-26-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azauracil derivs. as thyroid receptor ligands)

RN 332933-26-3 CAPLUS

CN 1,2,4-Triazine-6-carboxylic acid, 2-[4-(3-bromo-4-methoxyphenoxy)-3,5-dimethylphenyl]-2,3,4,5-tetrahydro-3,5-dioxo-, 2-[4-(4-acetylphenyl)-1-piperazinyl]ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

OMe

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      44.39     423.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -5.60      -8.00

FILE 'REGISTRY' ENTERED AT 17:55:11 ON 30 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 JUN 2008  HIGHEST RN 1031692-95-1
DICTIONARY FILE UPDATES:  29 JUN 2008  HIGHEST RN 1031692-95-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10567310last.str
```





chain nodes :
14 15 16 18 19 20 21 24 25 26 27 28 29 30 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
5-8 7-24 7-25 9-30 9-31 10-28 10-29 11-14 12-26 12-27 14-18 14-15 15-16
19-20 19-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
5-8 7-8 7-12 7-24 7-25 8-9 9-10 9-30 9-31 10-11 10-28 10-29 11-12
11-14 12-26 12-27 14-18 14-15 15-16 19-20 19-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 :

G1:Cb,Ak

G2:H,O

G3:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 16:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 23:Atom 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS

L7 STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7 STR



G1 Cb,Ak

G2 H,O

G3 C,H

Structure attributes must be viewed using STN Express query preparation.

```
=> s l7 full
FULL SEARCH INITIATED 17:55:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   223433 TO ITERATE

100.0% PROCESSED   223433 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.03

L8            0 SEA SSS FUL L7

=> d his

     (FILE 'HOME' ENTERED AT 17:39:05 ON 30 JUN 2008)

     FILE 'REGISTRY' ENTERED AT 17:39:14 ON 30 JUN 2008
L1              STRUCTURE UPLOADED
L2           14 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 17:40:00 ON 30 JUN 2008
L3            3 S L2 FULL

     FILE 'REGISTRY' ENTERED AT 17:47:00 ON 30 JUN 2008
L4              STRUCTURE UPLOADED
L5          117 S L4 FULL

     FILE 'CAPLUS' ENTERED AT 17:47:32 ON 30 JUN 2008
L6            7 S L5 FULL

     FILE 'REGISTRY' ENTERED AT 17:55:11 ON 30 JUN 2008
L7              STRUCTURE UPLOADED
L8            0 S L7 FULL
```

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   178.82     602.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -8.00

STN INTERNATIONAL LOGOFF AT 17:56:32 ON 30 JUN 2008
```